Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia

Haematologica. 2022 Jan 1;107(1):334-337. doi: 10.3324/haematol.2020.263715.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Clonal Evolution / genetics
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Piperidines
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Piperidines
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • ibrutinib
  • Adenine

Grants and funding

Funding: the authors wish to thank the Associazione Italiana per la Ricerca sul Cancro (AIRC), Metastases Special Program, N° 21198, Milan, Italy (RF); Progetti di Rilevante Interesse Nazionale (PRIN) 2015ZMRFEA (RF, AC).